Technology | Magnetic Resonance Imaging (MRI) | February 12, 2018

FDA Clears Canon Medical Systems’ New Vantage Galan 3.0T XGO Edition MRI

System equipped with new Saturn X gradient for expanded neuro and cardiac MR capabilities 

Vantage Galan 3T XGO Edition MRI system was cleared by the FDA.

February 12, 2018 — Physicians now have access to more neuro and cardiac magnetic resonance imaging (MRI) capabilities with the Vantage Galan 3.0T XGO Edition from Canon Medical Systems USA, Inc. Outfitted with the all-new Saturn X Gradient, the system can provide up to 30 percent improved signal-to-noise ratio (SNR) for brain diffusion weighted imaging (DWI), resulting in even higher resolution neuro images than previously offered. The newly FDA-cleared system enables sequences for quantitative analysis and allows cardiac exams to be completed with fewer breath holds and improved patient comfort.

The Galan 3T XGO Edition offers the ability to conduct quick, comfortable and high-quality neuro imaging exams, and allows for faster sampling and higher-resolution images, thanks to PURERF and Saturn technologies. This, combined with the ability to stack protocol sequences, results in quick neuro exams, enabling healthcare providers to produce higher resolution images for myriad neuro exams in under five minutes. Initial indications suggest the following neuro sequences can be performed in under five minutes: SAG T1, AX T2, AX T2 FLAIR, AX T2 and AX DWI/ADC. New software that comes with the system also offers MultiBand SPEEDER technology, which allows for multiple slices to be acquired at the same time, reducing diffusion weighted imaging scan times by up to two times.

The Galan 3T XGO Edition also delivers enhanced cardiac capabilities, including T1 mapping that utilizes Modified Look-Locker Inversion recovery (MOLLI) sequence and allows providers to acquire a more quantitative characterization of myocardial tissue within a single breath hold. The system’s Phase Sensitive Inversion Recovery (PSIR) in the heart provides improved contrast in late-enhanced imaging and eliminates the need for inversion time (TI) calibration scan, allowing cardiac exams to be completed with fewer breath holds and greater patient comfort.

“The new Galan 3T XGO Edition with Saturn X Gradient builds on the strengths of its predecessor and expands the versatility of MR even further with faster and higher resolution images, so that physicians don’t have to sacrifice accuracy or patient comfort for speed,” said Dominic Smith, senior director, CT, PET/CT, and MR business units, Canon Medical Systems USA. “With the help of this new advanced gradient and imaging package, health care providers can better meet their patients’ diverse needs, while continuing to provide a quiet and comfortable experience.”

For more information: us.medical.canon

Related Content

Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe.

A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | October 22, 2020
October 22, 2020 — According to an open-...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
According to an inquest, a man with a heart disorder and chest pain died two days after a doctor viewed the wrong scan and sent him home
News | Computed Tomography (CT) | October 21, 2020
October 21, 2020 — The BBC News
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...